Lutetium Lu 177 Vipivotide Tetraxetan trials for Castration-Resistant Prostate Carcinoma

All Lutetium Lu 177 Vipivotide Tetraxetan trials · All Castration-Resistant Prostate Carcinoma trials

Phase breakdown

Recruiting trials studying Lutetium Lu 177 Vipivotide Tetraxetan for Castration-Resistant Prostate Carcinoma

• Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
  NCT06288113 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
  NCT06145633 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location

Common questions

How many trials study Lutetium Lu 177 Vipivotide Tetraxetan for Castration-Resistant Prostate Carcinoma?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.